HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial

INTRODUCTION: A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug‐resistant virus that could spread and reduce the effectiveness of non‐nucleoside reverse transcriptase (NNRTI)‐based first‐line antiretroviral therapy. We evaluated HIV‐1 seroconversions...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Urvi M., Penrose, Kerri J., Heaps, Amy L., Halvas, Elias K., Goetz, B. Jay, Gordon, Kelley C., Hardesty, Russell, Sethi, Rahil, Schwarzmann, William, Szydlo, Daniel W., Husnik, Marla J., Chandran, Uma, Palanee‐Phillips, Thesla, Baeten, Jared M., Mellors, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583424/
https://www.ncbi.nlm.nih.gov/pubmed/34762770
http://dx.doi.org/10.1002/jia2.25833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583424/
https://www.ncbi.nlm.nih.gov/pubmed/34762770
http://dx.doi.org/10.1002/jia2.25833

Ejemplares similares